Key Findings
- Across 10 RCTs (531 participants), curcumin was associated with a significant reduction in depressive symptoms versus placebo (Hedge's g = −0.75; 95% CI −1.11 to −0.39).
- Several trials studied curcumin as an add-on to standard antidepressant care rather than as a standalone treatment.
- Effects on anxiety symptoms were also reported in a subset of trials, though fewer studies examined this outcome.
- All included trials were short (about 4–8 weeks), so longer-term efficacy and safety remain unestablished, and heterogeneity between trials was high.